The asia-pacific contraceptives market size was valued at USD 6.14 billion in 2024. The asia-pacific contraceptives market size is expected to have 6.95 % CAGR from 2025 to 2033 and be worth USD 11.24 billion by 2033 from USD 6.57 billion in 2025.
Increasing awareness about contraceptive methods among the population is the primary factor for the market's growth. Due to the increasing literacy rate in the region, more than half of the population are known about contraceptive methods. In India, most people use IUDs (Intrauterine devices) contraceptive methods to prevent pregnancy. With the increasing success rate of these devices for contraceptive plans, married women are showing interest in adopting contraceptive methods to avoid unexpected pregnancies.
The increasing development of various contraceptive methods is another factor driving the market growth forward. In addition, increasing manufacturing of over-the-counter drugs by large pharmaceutical companies also helps with market growth. Increasing investment and research on the development of various types of products, drugs, and devices and increasing government support for the manufacturing of drugs is the other reason which helps the growth of the market. Furthermore, increasing clinical trials for decreasing the side effects of the pills and the devices used for the contraceptive and increasing clinical trials on new contraceptive methods such as using gels also demand the market during the forecast period. Additionally, increasing development of the application regarding the use of contraceptive pills by the developer also helps the market growth.
Increasing health risks after using the contraceptive method among many women is the primary factor restraining the market growth. In addition, the availability of alternative methods to prevent pregnancy and the lack of acceptance of these contraceptive methods among a few populations and areas also hampers the market growth in this region. Furthermore, the other factors that impede market growth are the lack of awareness about contraceptive methods, the long time for approval of the products and drugs, and the lack of skilled healthcare professionals in contraceptive surgeries.
Asia pacific holds the maximum share in the market growth due to increasing employed women and healthcare expenditures and increasing awareness programs by the healthcare organization and the government to use contraceptive methods for family women to prevent several pregnancies from controlling the heavy population in the region. They also inform people of the complication of having several pregnancies for a woman, which affects their health in the future. In addition, they are providing information regarding contraceptive methods through advertisements to aware people who are uneducated and living in rural areas.
China holds the maximum share in the market growth. China is one of the highest uses of contraceptives among the population. Nearly 84 percent of women use contraceptive methods after marriage and after the children's birth. Due to increasing government policies and traditions, rural have an increased impact on contraceptive methods in China. China's family planning policies target married women to take birth control options to manage the population in the country. Young people have no rule to use contraceptives in this county because they are unmarried. These people use contraceptive methods such as condoms and oral pills for abortion to prevent pregnancy. All these factors help develop market growth in the Asia Pacific region.
Increasing approval of the drugs is the main factor for the market's growth in Japan. Most of the Japan people are using condoms as a contraceptive way. The Pandemic provides an opportunity for the growth of contraceptive methods because a large number of populations during the pandemic period stay at home. Japan's government takes several measures to approve oral drugs to reduce the risk for women.
A few of the notable companies dominating the APAC contraceptives market are Bayer HealthCare AG, Teva Pharmaceutical Industries Limited, Medisafe Distribution Inc, Pace Pharmaceuticals Inc., Medicines360, Church & Dwight, Co., Inc., Actavis, Inc., CooperSurgical, Inc., Merck & Co., Inc., Reckitt Benckiser plc, Mayer Laboratories, Inc., and Pfizer, Inc.
By Drug Type
By Medical Devices
By End User
By Country
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region